JP2011523937A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011523937A5 JP2011523937A5 JP2010548687A JP2010548687A JP2011523937A5 JP 2011523937 A5 JP2011523937 A5 JP 2011523937A5 JP 2010548687 A JP2010548687 A JP 2010548687A JP 2010548687 A JP2010548687 A JP 2010548687A JP 2011523937 A5 JP2011523937 A5 JP 2011523937A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- peptide
- iqgap3
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 70
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 57
- 150000001413 amino acids Chemical class 0.000 claims description 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 229940024606 amino acid Drugs 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 15
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 10
- 210000001808 exosome Anatomy 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 4
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 230000002980 postoperative effect Effects 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 36
- 102100037850 Interferon gamma Human genes 0.000 description 33
- 108010074328 Interferon-gamma Proteins 0.000 description 33
- 238000004519 manufacturing process Methods 0.000 description 26
- 101000994788 Homo sapiens Ras GTPase-activating-like protein IQGAP3 Proteins 0.000 description 16
- 108010075704 HLA-A Antigens Proteins 0.000 description 12
- 102000011786 HLA-A Antigens Human genes 0.000 description 12
- 102100034417 Ras GTPase-activating-like protein IQGAP3 Human genes 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000012286 ELISA Assay Methods 0.000 description 4
- 238000011510 Elispot assay Methods 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 4
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101150105203 IQGAP3 gene Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6053808P | 2008-06-11 | 2008-06-11 | |
| US61/060,538 | 2008-06-11 | ||
| PCT/JP2009/002613 WO2009150835A1 (en) | 2008-06-11 | 2009-06-10 | Iqgap3 epitope peptides and vaccines containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011523937A JP2011523937A (ja) | 2011-08-25 |
| JP2011523937A5 true JP2011523937A5 (enExample) | 2012-07-26 |
Family
ID=41416549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010548687A Withdrawn JP2011523937A (ja) | 2008-06-11 | 2009-06-10 | Ｉｑｇａｐ３エピトープペプチドおよびそれを含むワクチン |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110200626A1 (enExample) |
| EP (1) | EP2303909A4 (enExample) |
| JP (1) | JP2011523937A (enExample) |
| KR (1) | KR20110036903A (enExample) |
| CN (1) | CN102119169A (enExample) |
| AU (1) | AU2009258788A1 (enExample) |
| BR (1) | BRPI0915527A2 (enExample) |
| CA (1) | CA2727485A1 (enExample) |
| IL (1) | IL209869A0 (enExample) |
| MX (1) | MX2010013680A (enExample) |
| RU (1) | RU2010154081A (enExample) |
| TW (1) | TW201000115A (enExample) |
| WO (1) | WO2009150835A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI580431B (zh) | 2008-08-19 | 2017-05-01 | 腫瘤療法 科學股份有限公司 | Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗 |
| TW201134480A (en) * | 2010-04-08 | 2011-10-16 | Oncotherapy Science Inc | CLUAP1 peptides and vaccines including the same |
| GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| TWI796642B (zh) | 2015-08-28 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架 |
| GB201520542D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| KR102292655B1 (ko) | 2017-04-26 | 2021-08-23 | 지브이에스 필트레이션, 인코포레이티드 | 다중 비드 에어 필터 씰 |
| CN112521455B (zh) * | 2020-12-08 | 2022-09-02 | 长春理工大学 | 一种检测膀胱癌抗原蛋白特异性的多肽及其应用 |
| CN118930633A (zh) * | 2023-05-12 | 2024-11-12 | 中国科学院深圳先进技术研究院 | 肿瘤相关抗原表位肽及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001064835A2 (en) * | 2000-02-28 | 2001-09-07 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| DE102004026135A1 (de) * | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| JP5109131B2 (ja) * | 2005-02-10 | 2012-12-26 | オンコセラピー・サイエンス株式会社 | 膀胱癌を診断する方法 |
| EP2305811A1 (en) * | 2005-07-27 | 2011-04-06 | Oncotherapy Science, Inc. | Method of diagnosing smal cell lung cancer |
| EP2311986B1 (en) * | 2005-07-27 | 2015-04-15 | Oncotherapy Science, Inc. | Method of diagnosing esophageal cancer |
-
2009
- 2009-06-09 TW TW098119196A patent/TW201000115A/zh unknown
- 2009-06-10 AU AU2009258788A patent/AU2009258788A1/en not_active Abandoned
- 2009-06-10 RU RU2010154081/04A patent/RU2010154081A/ru not_active Application Discontinuation
- 2009-06-10 JP JP2010548687A patent/JP2011523937A/ja not_active Withdrawn
- 2009-06-10 CN CN2009801312154A patent/CN102119169A/zh active Pending
- 2009-06-10 EP EP09762266A patent/EP2303909A4/en not_active Withdrawn
- 2009-06-10 US US12/997,517 patent/US20110200626A1/en not_active Abandoned
- 2009-06-10 BR BRPI0915527A patent/BRPI0915527A2/pt not_active IP Right Cessation
- 2009-06-10 CA CA2727485A patent/CA2727485A1/en not_active Abandoned
- 2009-06-10 KR KR1020117000473A patent/KR20110036903A/ko not_active Withdrawn
- 2009-06-10 WO PCT/JP2009/002613 patent/WO2009150835A1/en not_active Ceased
- 2009-06-10 MX MX2010013680A patent/MX2010013680A/es not_active Application Discontinuation
-
2010
- 2010-12-09 IL IL209869A patent/IL209869A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011523937A5 (enExample) | ||
| US11098284B2 (en) | Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression | |
| JP6081483B2 (ja) | Ｔ細胞を増殖させるプロセス | |
| CA2459713C (en) | Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response | |
| JP2020124214A (ja) | 自己癌抗原特異的ｃｄ８＋ｔ細胞の分離及び増殖方法 | |
| JP4406566B2 (ja) | 細胞傷害性リンパ球の製造方法 | |
| CN110241086A (zh) | 用于过继细胞疗法的改进的细胞培养方法 | |
| US20120238012A1 (en) | Cytotoxic t lymphocyte | |
| RU2761653C2 (ru) | Пептиды и способы для лечения диабета | |
| Salgaller et al. | Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide | |
| US8232101B2 (en) | Identification of antigenic peptides from multiple myeloma cells | |
| CN102119171A (zh) | Cdca1表位肽及包含它的疫苗 | |
| TWI441648B (zh) | Ｆｏｘｐ３胜肽疫苗 | |
| CN102119169A (zh) | Iqgap3表位肽及包含它的疫苗 | |
| EP3176258B1 (en) | Method for preparing dendritic cell, dendritic cell prepared thereby, and use thereof | |
| de Jong et al. | Rapid enrichment of human papillomavirus (HPV)‐specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer | |
| JP2018510644A (ja) | 治療およびエピトープマッピング用Ｔ細胞の感作および増殖のためのｉｎ ｖｉｔｒｏ人工リンパ節 | |
| JP2020055845A (ja) | 単離されたドナーｍｈｃ由来ペプチド及びその使用 | |
| Kim et al. | Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination | |
| JP4936626B2 (ja) | 癌およびその前段階に対する個体の免疫 | |
| Shao et al. | Engineered cells for costimulatory enhancement combined with IL-21 enhance the generation of PD-1-disrupted CTLs for adoptive immunotherapy | |
| JP5155368B2 (ja) | 細胞傷害性ｔリンパ球 | |
| Himoudi et al. | Development of anti-PAX3 immune responses; a target for cancer immunotherapy | |
| WO2024044716A2 (en) | Tethered interleukin-2 recombinant receptors and methods of use | |
| HK1157819B (en) | Compositions and methods for priming monocytic dendritic cells and t cells for th1 response |